FMF Clinical Trial
Official title:
Are Mast Cells Involved in Autoinflammatory Diseases
Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).Our aim is to evaluate the involvement of MC in AID by assessing clinical and biological signs of MC activation and studying cutaneous and digestive biopsies.
Autoinflammatory diseases (AID) are caused by innate immunity dysregulation and characterized by recurrent bouts of fever, frequently associated with digestive, articular or cutaneous symptoms, and sometimes ocular, auricular or neurologic inflammation. The most frequent monogenic AID is Familial Mediterranean fever (FMF). Despite recent genetic progress AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome (MCAS). In MCAS, patients have various symptoms including abdominal pain, bloating, pruritus, flush, anxiety, fatigue, among which some are similar to those seen in patients with AID. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS). Our hypothesis is that MC could be involved in AID pathophysiology, In order to test this hypothesis, we plan to study : - clinical MC activation symptoms via a standardized clinical score - biological MC mediators : by measuring total serum tryptase and histamine in total blood, plasma and urine - MC infiltration on gastro-intestinal (GI) tract and cutaneous biopsies We will compare clinical MC activation score in AID patients to patients with mastocytosis, with other inflammatory diseases, and with healthy controls. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05190991 -
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
|
Phase 2 | |
Recruiting |
NCT03210610 -
Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients
|
||
Not yet recruiting |
NCT06336733 -
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
|
Phase 3 | |
Enrolling by invitation |
NCT04402255 -
Pilates Based Exercises in Patients With Behçet and Familial Mediterranean Fever.
|
N/A | |
Completed |
NCT02466217 -
Phenomics in Autoimmune and Inflammatory Diseases
|
||
Recruiting |
NCT05980780 -
The Effect of Video Game on Children With Familial Mediterranean Fever
|
N/A | |
Completed |
NCT05398536 -
Kinesiophobia in Familial Mediterranean Fever
|
||
Not yet recruiting |
NCT06047938 -
FMF and Atheroscelerosis
|
||
Recruiting |
NCT05092776 -
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
|
Phase 2 | |
Enrolling by invitation |
NCT04403438 -
Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic
|